Search…

Innovative Medical (002173.SZ) releases first quarter financial results, with a net loss attributable to shareholders of 13.9374 million yuan.

27/04/2025

Investment Express App News, Innovation Medical (002173.SZ) released its first quarter report for 2025. In the first quarter, the company achieved operating income of 193 million yuan, a year-on-year decrease of 3.98%. The net loss attributable to shareholders of the listed company was 13.93 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 14.97 million yuan.

Latest

9 m ago

How can trade issues be resolved? The European Central Bank is still prepared to cut interest rates in June to address the economic trauma caused by Trump.

17 m ago

The Prime Minister: Currently, there is no "specific threat" targeting Canadians.

23 m ago

According to a brief AI news alert, Minsheng Securities released a research report on April 27 recommending a buy rating for Yuanli Shares (300174.SZ). The main reasons for the rating include: 1) the expansion of the production and sales scale of activated carbon, and the stable leading position; 2) the improved profitability of sodium silicate, with significant synergies in the industrial chain. (Daily Economic News)

25 m ago

According to the AI Fast News of Netease, Pacific Securities released a research report on April 27, giving Mio Exhibition (300795.SZ) a buy rating. The rating reasons mainly include: 1) the performance of 2024 is under pressure due to the impact of the market environment; 2) the gross profit margin is steadily increasing, with a slight fluctuation in the expense ratio; 3) expanding into emerging markets, specialized exhibition management to enhance brand competitiveness; 4) digitization transformation to build industry barriers, data-driven precise services. (Daily Economic News)

26 m ago

Every AI brief, on April 27th, Minsheng Securities released a research report giving a buy rating to Youfa Group (601686.SH). The main reasons for the rating include: 1) Review: a slight decrease in production and sales volume, improvement in gross profit margin on a year-on-year basis in Q4 2024, and continuous growth in dividend yield; 2) Future core highlights: against the trend, increase market share, expand overseas layout nationwide. (Daily Economic News)

See all latest